地特胰岛素、格列美脲联合阿卡波糖治疗继发性磺脲类药物失效T2DM患者的效果分析  

Effect of Insulin Detemir and Glimepiride Combined with Acarbose in the Treatment of Patients with Secondary Sulfonylurea Failure T2DM

作　　者：陈彩秀 邓国宝 许伍华 朱锦辉 CHEN Caixiu;DENG Guobao;XU Wuhua;ZHU Jinhui(Shaoguan First People’s Hospital,Shaoguan 512025,China;不详)

机构地区：[1]广东省韶关市第一人民医院,广东韶关512025

出　　处：《中国医学创新》2020年第25期64-67,共4页Medical Innovation of China

摘　　要：目的:探讨地特胰岛素、格列美脲联合阿卡波糖治疗继发性磺脲类药物失效2型糖尿病(T2DM)患者的效果。方法:选取2016年3月-2019年2月于本院就诊的继发性磺脲类药物失效的T2DM患者78例,按照随机数字表法分为对照组与研究组,各39例。对照组行地特胰岛素联合格列美脲治疗,研究组在对照组的基础上加用阿卡波糖治疗。比较两组治疗效果、治疗前后血糖指标、C肽水平及不良反应发生情况。结果:研究组治疗总有效率为94.87%高于对照组的74.36%(P<0.05)。治疗后,研究组空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2 hours plasma glucose,2 h PG)及糖化血红蛋白(glycosylated hemoglobin,HbA1c)水平均低于对照组(P<0.05)。治疗后,研究组空腹C肽(CP0)与餐后2 h C肽(CP120)水平均高于对照组(P<0.05)。研究组不良反应发生率为7.69%低于对照组的28.21%(P<0.05)。结论:地特胰岛素、格列美脲联合阿卡波糖治疗继发性磺脲类药物失效T2DM患者临床效果较好,可显著降低血糖,改善患者胰岛β细胞功能,且安全性较好,可临床推广。Objective:To investigate the effect of Insulin Detemir and Glimepirea combined with Acarbose in the treatment of type 2 diabetes mellitus(T2DM)with secondary sulfonylurea failure.Method:A total of 78 T2DM patients with secondary sulfonylurea drug failure admitted to our hospital from March 2016 to February 2019 were selected.They were divided into control group and study group according to the random number table method,39 cases in each group.The control group was treated with Insulin Detemir combined with Glimepirea,and the study group was treated with Acarbose on the basis of the control group.The treatment effect,blood glucose index,C-peptide level before and after treatment and adverse reactions of the two groups were compared.Result:The total effective rate of treatment in the study group was 94.87%higher than 74.36%in the control group(P<0.05).After treatment,the fasting plasma glucose(FPG),2 hours plasma glucose(2 h PG)and glycosylated hemoglobin(HbA1c)levels were lower than those of the control group(P<0.05).After treatment,the levels of fasting C-peptide(CP0)and 2 h postprandial C-peptide(CP120)in the study group were higher than those in the control group(P<0.05).The incidence of adverse reactions in the study group was 7.69%lower than 28.21%in the control group(P<0.05).Conclusion:Insulin Detemir and Glimepiride combined with Acarbose in the treatment of secondary failure of sulfonylureas in T2DM patients has good clinical effect.It can significantly reduce blood glucose,improve the function of pancreaticβcells,and has good safety,which can be promoted in clinical practice.

关 键 词：地特胰岛素 格列美脲 阿卡波糖 继发性磺脲类药物失效 2型糖尿病 C肽 

分 类 号：R587.1[医药卫生—内分泌]